Uncategorized
Luminopia One, a Digital Therapeutic for Amblyopia, Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Luminopia today announced the publication of positive Phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia OneTM—in OphthalmologyⓇ, the journal of the American Academy of Ophthalmology. This is the first successful randomized controlled trial of a novel amblyopia treatment in more than a decade, and the results provide strong evidence supporting a potential new therapy for millions of patients. Unlike current treatment options, which c